Literature DB >> 22833339

Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis.

Helder I Nakaya1, Joy Gardner, Yee-Suan Poo, Lee Major, Bali Pulendran, Andreas Suhrbier.   

Abstract

OBJECTIVE: Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes a chronic debilitating polyarthralgia/polyarthritis, for which current treatments are often inadequate. To assess whether new drugs being developed for rheumatoid arthritis (RA) might find utility in the treatment of alphaviral arthritides, we sought to determine whether the inflammatory gene expression signature of CHIKV arthritis shows any similarities with RA or collagen-induced arthritis (CIA), a mouse model of RA.
METHODS: Using a recently developed animal model of CHIKV arthritis in adult wild-type mice, we generated a consensus CHIKV arthritis gene expression signature, which was used to interrogate publicly available microarray studies of RA and CIA. Pathway analyses were then performed using the overlapping gene signatures.
RESULTS: Gene set enrichment analysis showed that there was a highly significant overlap in the differentially expressed genes in the CHIKV arthritis model and in RA. This concordance also increased with the severity of RA, as measured by the inflammation score. A highly significant overlap was also seen between CHIKV arthritis and CIA. Pathway analysis revealed that the overlap between these arthritides was spread over a range of different inflammatory processes. Involvement of T cells and interferon-γ (IFNγ) in CHIKV arthritis was confirmed in studies of MHCII-deficient mice and IFNγ-deficient mice, respectively.
CONCLUSION: These results suggest that RA, a chronic autoimmune arthritis, and CHIKV disease, usually a self-limiting viral arthropathy, share multiple inflammatory processes. New drugs and biologic therapies being developed for RA may thus find application in the treatment of alphaviral arthritides.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22833339      PMCID: PMC3836361          DOI: 10.1002/art.34631

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  50 in total

1.  Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis.

Authors:  Ali Zaid; Nestor E Rulli; Michael S Rolph; Andreas Suhrbier; Suresh Mahalingam
Journal:  Arthritis Rheum       Date:  2011-02

2.  Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis.

Authors:  Thomas E Morrison; Alan C Whitmore; Reed S Shabman; Brett A Lidbury; Suresh Mahalingam; Mark T Heise
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  Emergence and clinical insights into the pathology of Chikungunya virus infection.

Authors:  Marie Christine Jaffar-Bandjee; Duksha Ramful; Bernard Alex Gauzere; Jean Jacques Hoarau; Pascale Krejbich-Trotot; Stephanie Robin; Anne Ribera; Jimmy Selambarom; Philippe Gasque
Journal:  Expert Rev Anti Infect Ther       Date:  2010-09       Impact factor: 5.091

Review 4.  New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.

Authors:  M Gema Bonilla-Hernán; M Eugenia Miranda-Carús; Emilio Martin-Mola
Journal:  Rheumatology (Oxford)       Date:  2011-05-26       Impact factor: 7.580

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis.

Authors:  U Ungethuem; T Haeupl; H Witt; D Koczan; V Krenn; H Huber; T M von Helversen; M Drungowski; C Seyfert; J Zacher; A Pruss; J Neidel; H Lehrach; H J Thiesen; P Ruiz; S Bläss
Journal:  Physiol Genomics       Date:  2010-09-21       Impact factor: 3.107

Review 7.  Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Authors:  Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

8.  Mice lacking all conventional MHC class II genes.

Authors:  L Madsen; N Labrecque; J Engberg; A Dierich; A Svejgaard; C Benoist; D Mathis; L Fugger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

9.  Macrophage-induced muscle pathology results in morbidity and mortality for Ross River virus-infected mice.

Authors:  B A Lidbury; C Simeonovic; G E Maxwell; I D Marshall; A J Hapel
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

10.  Complement receptor 3 promotes severe ross river virus-induced disease.

Authors:  Thomas E Morrison; Jason D Simmons; Mark T Heise
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

View more
  52 in total

1.  Identification of potential serum biomarkers for rheumatoid arthritis by high-resolution quantitative proteomic analysis.

Authors:  Yongjing Cheng; Yuling Chen; Xiaolin Sun; Yuhui Li; Cibo Huang; Haiteng Deng; Zhanguo Li
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

2.  Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis.

Authors:  Jonathan J Miner; Lindsey E Cook; Jun P Hong; Amber M Smith; Justin M Richner; Raeann M Shimak; Alissa R Young; Kristen Monte; Subhajit Poddar; James E Crowe; Deborah J Lenschow; Michael S Diamond
Journal:  Sci Transl Med       Date:  2017-02-01       Impact factor: 17.956

Review 3.  Development of Vaccines for Chikungunya Fever.

Authors:  Jesse H Erasmus; Shannan L Rossi; Scott C Weaver
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

4.  Closing the gap between viral and noninfectious arthritis.

Authors:  Kate D Ryman; William B Klimstra
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

5.  Mechanisms underlying the pathogenesis of arthritogenic alphaviruses: host immune responses and virus persistence.

Authors:  David W Hawman; Kristina S Burrack; Thomas E Morrison
Journal:  Future Virol       Date:  2014-06-16       Impact factor: 1.831

6.  Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

Authors:  Pierre Roques; Karl Ljungberg; Beate M Kümmerer; Leslie Gosse; Nathalie Dereuddre-Bosquet; Nicolas Tchitchek; David Hallengärd; Juan García-Arriaza; Andreas Meinke; Mariano Esteban; Andres Merits; Roger Le Grand; Peter Liljeström
Journal:  JCI Insight       Date:  2017-03-23

7.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

8.  The role of innate versus adaptive immune responses in a mouse model of O'nyong-nyong virus infection.

Authors:  Robert L Seymour; Shannan L Rossi; Nicholas A Bergren; Kenneth S Plante; Scott C Weaver
Journal:  Am J Trop Med Hyg       Date:  2013-04-08       Impact factor: 2.345

9.  Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Authors:  Pankaj Pal; Julie M Fox; David W Hawman; Yan-Jang S Huang; Ilhem Messaoudi; Craig Kreklywich; Michael Denton; Alfred W Legasse; Patricia P Smith; Syd Johnson; Michael K Axthelm; Dana L Vanlandingham; Daniel N Streblow; Stephen Higgs; Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

10.  CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis.

Authors:  Yee Suan Poo; Helder Nakaya; Joy Gardner; Thibaut Larcher; Wayne A Schroder; Thuy T Le; Lee D Major; Andreas Suhrbier
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.